Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Study
  • Published:

Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy

Nature Clinical Practice Rheumatology volume 3, pages 414–419 (2007)Cite this article

Abstract

Background A 54-year-old man with a 22-year history of rheumatoid arthritis and an 8-year history of chronic obstructive pulmonary disease presented with dyspnea on exertion, nonproductive cough and fatigue of 1 month's duration. His medication at presentation consisted of etanercept, azathioprine, naproxen and inhaled fluticasone and salbutamol.

Investigations At presentation, the patient underwent physical examination, chest X-ray and high-resolution CT, blood tests, and bronchoalveolar lavage fluid analysis including auramine stains and gene sequence analysis of cultured Mycobacterium szulgai. The patient underwent minithoracotomy after 6 months, and bronchoalveolar lavage fluid analysis, culture and chest X-ray after 18 months. Further chest imaging and culture of sputum samples were performed another year later.

Diagnosis Pulmonary M. szulgai infection.

Management Triple drug therapy with rifampicin, ethambutol hydrochloride and clarithromycin. Anti-tumor necrosis factor treatment was continued.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The patient's chest X-rays
Figure 2: The patient's CT images
Figure 3: Microbiological and serological parameters during the course of the patient's disease
Figure 4: A photograph of genotyping results of the patient's Mycobacterium szulgai isolates

References

  1. American Thoracic Society (1997) Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 156: S1–S25

  2. Zhang Q et al. (2002) Pseudoepidemic due to a unique strain of Mycobacterium szulgai: genotypic, phenotypic, and epidemiological analysis. J Clin Microbiol 40: 1134–1139

    Article  Google Scholar 

  3. Jeong YJ et al. (2004) Nontuberculous mycobacterial pulmonary infection in immunocompetent patients: comparison of thin-section CT and histopathologic findings. Radiology 231: 880–886

    Article  Google Scholar 

  4. Ishige I et al. (1999) Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet 354: 120–123

    Article  CAS  Google Scholar 

  5. Doty JD et al. (2005) Treatment of sarcoidosis with infliximab. Chest 127: 1064–1071

    Article  CAS  Google Scholar 

  6. Gonzalez-Lopez MA et al. (2006) Development of sarcoidosis during etanercept therapy. Arthritis Rheum 55: 817–820

    Article  Google Scholar 

  7. Saliu OY et al. (2006) Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194: 486–492

    Article  CAS  Google Scholar 

  8. Gardam MA et al. (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3: 148–155

    Article  CAS  Google Scholar 

  9. Wallis RS et al. (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38: 1261–1265

    Article  CAS  Google Scholar 

  10. Mufti AH et al. (2005) Mycobacterium abscessus infection after use of tumor necrosis factor α inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor α use. Diagn Microbiol Infect Dis 53: 233–238

    Article  CAS  Google Scholar 

  11. Phillips K et al. (2002) Experience with etanercept in an academic medical centre: are infection rates increased? Arthritis Rheum 47: 17–21

    Article  CAS  Google Scholar 

  12. Wallis RS (2005) Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 41: 201–208

    Article  CAS  Google Scholar 

  13. Garcia Vidal C et al. (2005) Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 40: 756–759

    Article  Google Scholar 

  14. Matsumoto T (2006) Infliximab for rheumatoid arthritis in a patient with tuberculosis. N Engl J Med 355: 740–741

    Article  CAS  Google Scholar 

  15. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society (2000) Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 55: 210–218

  16. Benator DA et al. (1997) Mycobacterium szulgai infection of the lung: case report and review of an unusual pathogen. Am J Med Sci 313: 346–351

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. and R Dekhuijzen is a Professor and Head of the Department of Pulmonary Diseases at the Radboud University, J van Ingen is a medical doctor and PhD candidate, M Boeree and W de Lange are Senior Staff Chest Physicians, Nijmegen Medical Centre. J van Ingen is also affiliated with, P de Haas is a Senior Analyst at, and D van Soolingen is the Head of, the National Mycobacteria Reference Laboratory, National Institute of Public Health and the Environment, Bilthoven. M Janssen is a Rheumatologist and E Ullmann is a Senior Staff Chest Physician in the Rijnstate Hospital in Arnhem, The Netherlands.,

    Jakko van Ingen, Martin Boeree, Matthijs Janssen, Erik Ullmann, Wiel de Lange, Petra de Haas, Richard Dekhuijzen & Dick van Soolingen

Authors
  1. Jakko van Ingen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Boeree
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthijs Janssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Erik Ullmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wiel de Lange
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Petra de Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Richard Dekhuijzen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dick van Soolingen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jakko van Ingen.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Ingen, J., Boeree, M., Janssen, M. et al. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Rev Rheumatol 3, 414–419 (2007). https://doi.org/10.1038/ncprheum0538

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0538

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing